Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations

US11446302B2 · kind B2 · utility

Assignee

• The Board of Regents of the University of Texas System · US

Inventors

• Jacqulyne ROBICHAUX · Manvel, US
• Monique NILSSON · Sugar Land, US
• John V. HEYMACH · Pearland, US

Key dates

• Filing date: Nov 17, 2017
• Grant date: Sep 20, 2022
• Expiry date: Mar 10, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/156
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.